HPA AXIS/SLEEP/GCRC

HPA 轴/睡眠/GCRC

• 批准号: 7375225
• 负责人: ALAN F. SCHATZBERG
• 金额: $ 3.25万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7375225
• 关键词: HPA; AXIS; SLEEP; GCRC

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The overall purpose of this study is to investigate the relationships in hypothalamic-pituitary adrenal (HPA) axis activity and sleep, and to assess whether altering the HPA axis activity and rhythm can help overcome insomnia. This double-blinded placebo controlled pilot study will explore the effects of mifepristone on circadian rhythms and sleep, in this case, in subjects with insomnia, via manipulation of HPA axis activity. This study will be performed using chronic insomnia subjects recruited from the community or the sleep clinic who demonstrate chronic insomnia. The subjects will be randomly assigned to receive either placebo or 600 mg of Mifepristone daily, for five days. At the start of the study, approximately two subjects will be assigned mifepristone open-label as a pilot trial. Subjects will be prospectively followed with measures to include actigraphy, polysomnography, sleep diaries and tympanic temperature, as well as both pre-treatment and two post-treatment hormonal assays obtained via overnight stays in the GCRC. We expect that subjects treated with mifepristone will eventually demonstrate a decrease in their total and evening cortisol levels. Furthermore, we expect that such a decrease in cortisol shall correlate with an improvement in sleep efficiency.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子弹和调查员（PI）可能已经从其他NIH来源获得了主要资金，因此可以在其他清晰的条目中代表。列出的机构适用于该中心，这不一定是调查员的机构。这项研究的总体目的是研究下丘脑 - 垂体肾上腺（HPA）轴活动和睡眠的关系，并评估改变HPA轴活动和节奏是否可以帮助克服失眠。这项双盲安慰剂控制的试点研究将通过操纵HPA轴活动来探索米非司酮对失眠受试者的昼夜节律和睡眠的影响。这项研究将使用从社区或表现出慢性失眠的睡眠诊所招募的慢性失眠对象进行。这些受试者每天将随机分配接受安慰剂或600毫克的米非酮，持续五天。在研究开始时，将大约两个受试者分配给米非司酮开放标签作为试验试验。将对受试者进行前瞻性遵循的措施，包括精神分裂症，多摄影术，睡眠日记和鼓膜温度，以及治疗前和两种通过在GCRC中过夜的治疗后荷尔蒙分析。我们预计，用米非司酮治疗的受试者最终将表现出其总皮质醇水平下降。此外，我们期望皮质醇的这种减少应与睡眠效率提高相关。